Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1.

Busch CJ, Kriegs M, Laban S, Tribius S, Knecht R, Petersen C, Dikomey E, Rieckmann T.

Radiother Oncol. 2013 Sep;108(3):495-9. doi: 10.1016/j.radonc.2013.06.035. Epub 2013 Aug 7.

PMID:
23932155
2.

The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines.

Güster JD, Weissleder SV, Busch CJ, Kriegs M, Petersen C, Knecht R, Dikomey E, Rieckmann T.

Radiother Oncol. 2014 Dec;113(3):345-51. doi: 10.1016/j.radonc.2014.10.011. Epub 2014 Nov 10.

PMID:
25467050
3.

HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity.

Rieckmann T, Tribius S, Grob TJ, Meyer F, Busch CJ, Petersen C, Dikomey E, Kriegs M.

Radiother Oncol. 2013 May;107(2):242-6. doi: 10.1016/j.radonc.2013.03.013. Epub 2013 Apr 17.

PMID:
23602369
4.

Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation and induction of apoptosis.

Arenz A, Ziemann F, Mayer C, Wittig A, Dreffke K, Preising S, Wagner S, Klussmann JP, Engenhart-Cabillic R, Wittekindt C.

Strahlenther Onkol. 2014 Sep;190(9):839-46. doi: 10.1007/s00066-014-0605-5. Epub 2014 Apr 9.

PMID:
24715240
5.

Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation.

DeWeese TL, Walsh JC, Dillehay LE, Kessis TD, Hedrick L, Cho KR, Nelson WG.

Int J Radiat Oncol Biol Phys. 1997 Jan 1;37(1):145-54.

PMID:
9054890
6.

Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells.

Sørensen BS, Busk M, Olthof N, Speel EJ, Horsman MR, Alsner J, Overgaard J.

Radiother Oncol. 2013 Sep;108(3):500-5. doi: 10.1016/j.radonc.2013.06.011. Epub 2013 Aug 13.

PMID:
23953409
7.

Different mechanisms of cell death in radiosensitive and radioresistant p53 mutated head and neck squamous cell carcinoma cell lines exposed to carbon ions and x-rays.

Maalouf M, Alphonse G, Colliaux A, Beuve M, Trajkovic-Bodennec S, Battiston-Montagne P, Testard I, Chapet O, Bajard M, Taucher-Scholz G, Fournier C, Rodriguez-Lafrasse C.

Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):200-9. doi: 10.1016/j.ijrobp.2009.01.012.

PMID:
19362238
8.

Effect of radiation on cell proliferation and tumor hypoxia in HPV-positive head and neck cancer in vivo models.

Sørensen BS, Busk M, Horsman MR, Alsner J, Overgaard J, Kyle AH, Minchinton AI.

Anticancer Res. 2014 Nov;34(11):6297-304.

PMID:
25368228
9.

Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation ± Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis.

Ziemann F, Arenz A, Preising S, Wittekindt C, Klussmann JP, Engenhart-Cabillic R, Wittig A.

Am J Cancer Res. 2015 Feb 15;5(3):1017-31. eCollection 2015.

10.
11.

Small molecules alter VEGFR and PTEN expression in HPV-positive and -negative SCC: new hope for targeted-therapy.

Aderhold C, Faber A, Umbreit C, Chakraborty A, Bockmayer A, Birk R, Sommer JU, Hörmann K, Schultz JD.

Anticancer Res. 2015 Mar;35(3):1389-99.

PMID:
25750290
13.

Targeted radiosensitization by the Chk1 inhibitor SAR-020106.

Borst GR, McLaughlin M, Kyula JN, Neijenhuis S, Khan A, Good J, Zaidi S, Powell NG, Meier P, Collins I, Garrett MD, Verheij M, Harrington KJ.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1110-8. doi: 10.1016/j.ijrobp.2012.08.006. Epub 2012 Sep 14.

PMID:
22981708
14.

The chemopreventive and clinically used agent curcumin sensitizes HPV (-) but not HPV (+) HNSCC to ionizing radiation, in vitro and in a mouse orthotopic model.

Tuttle S, Hertan L, Daurio N, Porter S, Kaushick C, Li D, Myamoto S, Lin A, O'Malley BW, Koumenis C.

Cancer Biol Ther. 2012 May;13(7):575-84. doi: 10.4161/cbt.19772. Epub 2012 May 1.

15.

p53-dependent Chk1 phosphorylation is required for maintenance of prolonged G2 Arrest.

Wang XQ, Stanbridge EJ, Lao X, Cai Q, Fan ST, Redpath JL.

Radiat Res. 2007 Dec;168(6):706-15.

PMID:
18088187
16.

Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines.

Nagel R, Martens-de Kemp SR, Buijze M, Jacobs G, Braakhuis BJ, Brakenhoff RH.

Oral Oncol. 2013 Jun;49(6):560-6. doi: 10.1016/j.oraloncology.2013.03.446. Epub 2013 Apr 8.

17.

Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.

Vance S, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, Maybaum J, Lawrence TS, Morgan MA.

Cell Cycle. 2011 Dec 15;10(24):4321-9. doi: 10.4161/cc.10.24.18661. Epub 2011 Dec 15.

18.

Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma.

Cooper T, Biron VL, Fast D, Tam R, Carey T, Shmulevitz M, Seikaly H.

J Otolaryngol Head Neck Surg. 2015 Feb 24;44:8. doi: 10.1186/s40463-015-0062-x.

19.

The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities.

Bonner JA, Maihle NJ, Folven BR, Christianson TJ, Spain K.

Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):243-7.

PMID:
8195014
20.

Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.

Schultz JD, Mühlheim K, Erben P, Hofheinz RD, Faber A, Thorn C, Sommer JU, Hörmann K, Sauter A.

Oncol Rep. 2011 Nov;26(5):1099-109. doi: 10.3892/or.2011.1403. Epub 2011 Jul 26.

PMID:
21805039
Items per page

Supplemental Content

Write to the Help Desk